Viewing Study NCT02279394


Ignite Creation Date: 2025-12-25 @ 1:32 AM
Ignite Modification Date: 2026-03-03 @ 9:16 PM
Study NCT ID: NCT02279394
Status: COMPLETED
Last Update Posted: 2023-06-09
First Post: 2014-09-26
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Sponsor: Dana-Farber Cancer Institute
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Smoldering Myeloma View
None Smoldering Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Smoldering myeloma View
None Smoldering Multiple Myeloma View